Editas Medicine receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Editas Medicine Inc (EDIT)
The Editas Medicine share price today is 3.11, view NASDAQ EDIT stock exchange data. Track the latest Editas Medicine share price with real-time updates on EDIT stock performance including market cap, day range, 52-week range and dividend yield. Access EDIT charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.95
3.25
52 wk Range
1.66
4.54
EDIT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.953.25
52 wk Range
1.664.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EDIT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
6.00
Upside
+92.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
Form 144 Editas Medicine For: 22 July- Investing.com
- Editas Medicine receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Form 4 Editas Medicine For: 30 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
4 Hold
2 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.00
(+92.93% Upside)
Editas Medicine Inc SWOT Analysis
Gene Editing Pionee | Editas Medicine leads in CRISPR/Cas9 technology, developing transformative therapies for genetic disorders with a focus on in vivo genome editing |
Financial Crossroads | Despite a $256M market cap and cash runway into 2027, Editas faces challenges with negative EPS forecasts and substantial R&D investments |
Pipeline Potential | Explore Editas' progress towards declaring two development candidates by mid-2025, including programs for Sickle Cell Disease and liver targets |
Market Outlook | Analysts maintain a cautious stance, with price targets ranging from $3 to $4, reflecting the complex landscape of gene editing therapeutics |
Earnings
Latest Release
05-08-2026
EPS / Forecast
-0.15 / -0.27
Revenue / Forecast
11.89M / 3M
Compare EDIT to Peers and Sector
Metrics to compare | EDIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEDITPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | −1.7x | −0.4x | |
PEG Ratio | −0.09 | −0.04 | 0.00 | |
Price/Book | 4.5x | 1.8x | 2.6x | |
Price / LTM Sales | 10.2x | 17.7x | 3.1x | |
Upside (Analyst Target) | 60.8% | 354.5% | 48.9% | |
Fair Value Upside | Unlock | 14.1% | 6.2% | Unlock |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Editas Medicine (EDIT) Share Price Today?
The Editas Medicine share price today is 3.11.
What is the current Editas Medicine (EDIT) share price and day range?
As of 23-08-2026, the Editas Medicine share price is 3.11, with a previous close of 2.94. The share price has ranged from 2.95 to 3.25 today, while the 52-week range spans from 1.66 to 4.54.
What Is the Editas Medicine Market Cap?
As of today, Editas Medicine market cap is 477.63M.
What Is the Editas Medicine (EDIT) Share Price Target?
The average 12-month share price target for Editas Medicine is 6.00, with a high estimate of 15 and a low estimate of 1. 7 analysts recommend buying, while 2 suggest selling, with an overall rating of Buy and +92.93% Upside potential.
What Is Editas Medicine's Earnings Per Share (TTM)?
The Editas Medicine EPS (TTM) is -0.73.
When Is the Next Editas Medicine Earnings Date?
Editas Medicine will release its next earnings report on 09-11-2026.
From a Technical Analysis Perspective, Is EDIT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Editas Medicine Trade On?
Editas Medicine is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Editas Medicine?
The stock symbol for Editas Medicine is "EDIT."
How Many Times Has Editas Medicine Stock Split?
Editas Medicine has split 0 times.
How Many Employees Does Editas Medicine Have?
Editas Medicine has 87 employees.
What Is the EDIT Premarket Price?
EDIT's last pre-market stock price is 2.98. The pre-market share volume is 14,890.00, and the stock has changed by 0.04, or 1.36%.
What Is the EDIT After Hours Price?
EDIT's last after hours stock price is 3.10, the stock has changed by -0.01, or -0.32%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.